Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia

International Journal of Psychiatry in Clinical Practice

Volumn 10, Issue 2, 2006, Pages 97-104

  Ko, Young Hoon ^a   Joe, Sook Haeng ^a   Cho, Woong ^b   Park, Jeong Hyun ^b   Lee, Jung Jae ^b   Jung, In Kwa ^a   Kim, Leen ^a   Kim, Seung Hyun ^a  

^a Korea University College of Medicine   (South Korea)

^b Bugok National Hospital   (South Korea)

Author keywords

Cognitive function; Negative symptoms; Oestrogen; Schizophrenia; Women

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO; QUETIAPINE; RISPERIDONE;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HORMONE SUBSTITUTION; HUMAN; MENTAL DISEASE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PREMENOPAUSE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECALL; SCHIZOPHRENIA; VISUAL MEMORY;

EID: 33745059338     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500500526235     Document Type: Article

References (62)

1. Robinson D, Friedman L, Marcus R, Tinklenberg J, Yesavage J. Estrogen replacement therapy and memory in older women. J Am Geriatr Soc 1994;42:919-22.
2. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994;83:979-83.
3. Schmidt R, Fazekas F, Reinhart B, Kapeller P, Fazekas G, Offenbacher H, et al. Estrogen replacement therapy in older women: A neuropsychological and brain MRI study. J Am Geriatr Soc 1996;44:1307-13.
4. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-95.
5. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51:896-900.
6. Henderson VW, Watt L, Buckwalter JG. Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Psychoneuroendocrinology 1996;21:421-30.
7. Riecher-Rossler A, Seeman MV. Oestrogens and schizophrenia-Introduction. Arch Women Ment Health 2002;5:91-2.
8. Kolsch H, Rao ML. Neuroprotective effects of estradiol-17beta: Implications for psychiatric disorders. Arch Women Ment Health 2002;5:105-10.
9. Goldstein JM, Tsuang MT, Faraone SV. Gender and schizophrenia: implications for understanding the heterogeneity of the illness. Psychiatry Res 1989;28:243-53.
10. Grimes DA, Lobo RA. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet Gynecol 2002;100:1344-53.
11. Goldstein JM. Gender differences in the course of schizophrenia. Am J Psychiatry 1988;145:684-9.
12. Pecins-Thompson M, Bethea CL. Ovarian steroid regulation of serotonin-1A autoreceptor messenger RNA expression in the dorsal raphe of rhesus macaques. Neuroscience 1999;89:267-77.
13. Lindamer LA, Lohr JB, Harris MJ, McAdams LA, Jeste DV. Gender-related clinical differences in older patients with schizophrenia. J Clin Psychiatry 1999;60:61-7.
14. Hafner H, Hambrecht M, Loffler W, Munk-Jorgensen P, Riecher-Rossler A. Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life-cycle. Psychol Med 1998;28:351-65.
15. Seeman MV. Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand 1986;73:609-17.
16. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. J Am Med Assoc 2003;289:2663-72.
17. Thompson K, Sergejew A, Kulkarni J. Estrogen affects cognition in women with psychosis. Psychiatry Res 2000; 94:201-9.
18. Hoff AL, Kremen WS, Wieneke MH, Lauriello J, Blankfeld HM, Faustman WO, et al. Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am J Psychiatry 2001;158:1134-9.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
20. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 1982;39:784-8.
21. Inada T. Evaluation and diagnosis of drug-induced extra-pyramidal symptoms: Commentary on DIEPSS and guide to its usage. Tokyo: Seiwa Shoten Publishers; 1996.
22. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-51.
23. Williams JM. Memory Assessment Scale. Professional manual. Odessa, FL: Psychological Assessment Resources; 1991.
24. Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia 1968;6:53-60.
25. Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery. Tucson, AZ: Neuropsychology Press; 1985.
26. Kaplan E, Fein D, Morris R. WAIR-R NI Manual. San Antonio, TX: Psychological Corporation; 1991.
27. Bozikas VP, Kosmidis MH, Kioperlidou K, Karavatos A. Relationship between psychopathology and cognitive functioning in schizophrenia. Compr Psychiatry 2004;45:392-400.
28. Voruganti LN, Heslegrave RJ, Awad AG. Neurocognitive correlates of positive and negative syndromes in schizophrenia. Can J Psychiatry 1997;42:1066-71.
29. Schuepbach D, Keshavan MS, Kmiec JA, Sweeney JA. Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia. Schizophr Res 2002;53:249-61.
30. Lindamer LA, Buse DC, Lohr JB, Jeste DV. Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 2001;49:47-51.
31. Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J, et al. Estrogen - A potential treatment for schizophrenia. Schizophr Res 2001;48:137-44.
32. Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1007-12.
33. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996;20:247-52.
34. Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992;149:587-95.
35. Fink G, Sumner BE, McQueen JK, Wilson H, Rosie R. Sex steroid control of mood, mental state and memory. Clin Exp Pharmacol Physiol 1998;25:764-75.
36. Hafner H, Behrens S, De Vry J, Gattaz WF. An animal model for the effects of estradiol on dopamine-mediated behavior: Implications for sex differences in schizophrenia. Psychiatry Res 1991;38:125-34.
37. Guivarc'h D, Vincent JD, Vernier P. Alternative splicing of the D2 dopamine receptor messenger ribonucleic acid is modulated by activated sex steroid receptors in the MMQ prolactin cell line. Endocrinology 1998;139:4213-21.
38. Kukstas LA, Domec C, Bascles L, Bonnet J, Verrier D, Israel JM, et al. Different expression of the two dopaminergic D2 receptors, D2415 and D2444, in two types of lactotroph each characterized by their response to dopamine, and modification of expression by sex steroids. Endocrinology 1991;129:1101-3.
39. Sumner BEH, Fink G. Estradiol-17-beta in its positive feedback mode significantly increases 5-Ht2A receptor density in the frontal, cingulate and piriform cortex of the female rat. J Physiol 1995;483P:52.
40. Raap DK, DonCarlos L, Garcia F, Muma NA, Wolf WA, Battaglia G, et al. Estrogen desensitizes 5-HT(1A) receptors and reduces levels of G(z), G(i1) and G(i3) proteins in the hypothalamus. Neuropharmacology 2000;39:1823-32.
41. Stip E, Mancini-Marie A. Cognitive function and depression in symptom resolution in schizophrenia patients treated with an atypical antipsychotic. Brain Cogn 2004;55:463-5.
42. Brebion G, Amador X, Smith M, Malaspina D, Sharif Z, Gorman JM. Depression, psychomotor retardation, negative symptoms, and memory in schizophrenia. Neuropsychiatry Neuropsychol Behav Neurol 2000;13:177-83.
43. Epperson CN, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med 1999;61:676-97.
44. Klaiber EL, Kobayashi Y, Broverman DM, Hall F. Plasma monoamine oxidase activity in regularly menstruating women and in amenorrheic women receiving cyclic treatment with estrogens and a progestin. J Clin Endocrinol Metab 1971;33:630-8.
45. Sichel DA, Cohen LS, Robertson LM, Ruttenberg A, Rosenbaum JF. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry 1995;38:814-8.
46. Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 1996;347:930-3.
47. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990;16:185-94.
48. Thompson KN, Kulkarni J, Sergejew AA. Extrapyramidal symptoms and oestrogen. Acta Psychiatr Scand 2000;101:130-4.
49. Judd HL. Oestrogen replacement therapy: Physiological considerations and new applications. Baillieres Clin Endocrinol Metab 1987;1:177-206.
50. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977;4:31-47.
51. Paganini-Hill A, Henderson VW. The effects of hormone replacement therapy, lipoprotein cholesterol levels, and other factors on a clock drawing task in older women. J Am Geriatr Soc 1996;44:818-22.
52. McEwen BS, Woolley CS. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol 1994;29:431-6.
53. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain: implications for cognition and aging. Neurology 1997;48:S8-15.
54. Drake EB, Henderson VW, Stanczyk FZ, McCleary CA, Brown WS, Smith CA, et al. Associations between circulating sex steroid hormones and cognition in normal elderly women. Neurology 2000;54:599-603.
55. Grodstein F, Chen J, Pollen DA, Albert MS, Wilson RS, Folstein MF, et al. Postmenopausal hormone therapy and cognitive function in healthy older women. J Am Geriatr Soc 2000;48:746-52.
56. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. J Am Med Assoc 2003;289:2651-62.
57. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. J Am Med Assoc 2004;291:2959-68.
58. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in post-menopausal women: Women's Health Initiative Memory Study. J Am Med Assoc 2004;291:2947-58.
59. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: A meta-analysis. Neuroscience 2000;101:485-512.
60. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. J Am Med Assoc 2001;285:1489-99.
61. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
62. Kuller LH. Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women's Health Initiative. Arterioscler Thromb Vasc Biol 2003;23:11-6.